Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01495364
Recruitment Status : Completed
First Posted : December 20, 2011
Last Update Posted : April 28, 2016
Information provided by (Responsible Party):
Lisata Therapeutics, Inc.

Brief Summary:
This study will assess the safety and efficacy of intracoronary artery administered autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial infarction (STEMI). This will be assessed by evaluating and comparing the autologous stem cell treatment group to the control group in terms of the occurrence of AE's, SAE's and Major Adverse Cardiac Events (MACE), by the change in myocardial perfusion (RTSS) measured quantitatively by gated single photon emission computed tomography myocardial perfusion imaging (gated SPECT MPI), and other secondary endpoints such as LVEF measured by cardiac MRI in addition to other endpoints.

Condition or disease Intervention/treatment Phase
ST Segment Elevation Myocardial Infarction Biological: NBS10 Other: placebo Phase 2

Detailed Description:
Efficacy endpoint is at 6 months. Clinical endpoints and safety will be measured through 36 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction.
Study Start Date : December 2011
Actual Primary Completion Date : June 2014
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: NBS10
active treatment - CD34+ cells
Biological: NBS10
dosage = 10 or more million CD34+ cells via intracoronary infusion
Other Name: AMR-001

Placebo Comparator: placebo
matching placebo
Other: placebo
matching placebo

Primary Outcome Measures :
  1. To determine safety and efficacy of intracoronary infusion of NBS10. [ Time Frame: primary outcome measured at 6 months ]
    The primary endpoint includes the occurrence of AE's, SAE's and Major Adverse Cardiac Events (MACE) and the assessment of myocardial perfusion measured by quantitative gated SPECT MPI specifically looking at resting total severity score.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 years or older.
  2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation > 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, CPK MB or both).

    Chest pain syndrome can extend to more than 3 days prior to admission if its course is consistent with transient/intermittent ischemia rather than symptoms that are continuous suggesting ongoing infarction extending beyond 3 days.

  3. Successful stent placement and reperfusion within 3 days of chest pain onset and with TIMI Flow score of 2 or 3 and infarct related artery (IRA) with <20% stenosis after revascularization.
  4. Wall motion abnormality associated with the target lesion
  5. NYHA heart failure class I, II or III.
  6. Study entry LVEF <48% determined by CMR no sooner than 96 hours from stent placement.
  7. Able to provide informed written consent and willing to participate in all required study follow-up assessments.
  8. Subjects must have an INR ≤ 2.0 within 2 days of the bone marrow collection.
  9. Subjects must have a Hgb ≥ 10 grams/dL, WBC ≥ 3500 cells/mm3, a platelet count ≥ 100,000 cells/mm3, serum creatinine ≤ 2.5, and total bilirubin ≤ 2.0 within 7 days of the bone marrow collection or by end of screening phase.
  10. Expected survival of at least one year.
  11. Females of child bearing potential agree to use birth control (barrier method accepted) for one month post bone marrow harvest.


  1. Continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.
  2. Subjects in cardiogenic shock (systolic pressure < 80mm/Hg, on vasopressors, or intra-aortic counterpulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.
  3. Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc).
  4. Subjects receiving warfarin who have an INR >2 or with major bleeding requiring active transfusion support.
  5. Subjects who require continuous anticoagulation during the time when the bone marrow harvest is scheduled, as heparin must be discontinued for 4 hours prior to and 24 hours after bone marrow harvest procedure. (See Appendix VII.)
  6. Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.
  7. Subjects with known severe immunodeficiency states (AIDS).
  8. Cirrhosis requiring active medical management.
  9. Malignancy requiring active treatment (except basal cell skin cancer).
  10. Subjects with documented active alcohol and /or other substance abuse.
  11. Females of child bearing potential unless a pregnancy test is negative within 7 days of the mini-bone marrow harvest.
  12. Re-occlusion of the IRA prior to the infusion procedure.
  13. Planned revascularization intervention during the next 6 months (A second PCI can be performed if done prior to qualifying CMR at least 96 hours post primary PCI).
  14. Participation in an ongoing investigational trial.
  15. Active or suspected bacterial infection requiring systemic intravenous antibiotics.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01495364

Show Show 58 study locations
Sponsors and Collaborators
Lisata Therapeutics, Inc.
Layout table for investigator information
Study Director: Tom Moss, MD Lisata Therapeutics, Inc.
Principal Investigator: Arshed Quyyumi, MD Emory University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lisata Therapeutics, Inc. Identifier: NCT01495364    
Other Study ID Numbers: 002
First Posted: December 20, 2011    Key Record Dates
Last Update Posted: April 28, 2016
Last Verified: April 2016
Keywords provided by Lisata Therapeutics, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
ST Elevation Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases